EMGALITY 120 mg/mL (Galcanezumab-Gnlm INJECTION, SOLUTION) 120 mg/mL

Galcanezumab-gnlm is a humanized monoclonal antibody that specifically binds to the CGRP ligand and blocks its interaction with the receptor. By inhibiting CGRP, EMGALITY helps to prevent the onset and reduce the frequency and severity of migraine and episodic cluster headaches.

The dosage of EMGALITY 120 mg/mL is determined by a healthcare provider based on the specific condition being treated. For migraine prevention, a loading dose of 240 mg (administered as two consecutive injections of 120 mg each) is followed by monthly doses of 120 mg. For episodic cluster headache, a 300 mg dose (administered as three consecutive injections of 100 mg each) is given at the onset of the cluster period, followed by monthly doses until the end of the cluster period.

The safety of EMGALITY 120 mg/mL during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using this medication during pregnancy or while breastfeeding.

To order EMGALITY 120 mg/mL from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping (including cold-chain where relevant), and the import paperwork.

EMGALITY 120 mg/mL is a CGRP antagonist specifically designed for the preventive treatment of migraine. Compared to other migraine treatments, it offers a targeted approach by blocking the CGRP ligand, which is involved in the pathogenesis of migraine. The choice of treatment depends on individual patient factors and should be discussed with a healthcare provider.

EMGALITY 120 mg/mL should be stored refrigerated at 2-8°C (36-46°F) in the original carton to protect it from light. It should not be frozen or shaken. The medication can be stored out of refrigeration in the original carton at temperatures up to 30°C (86°F) for up to 7 days. Once stored out of refrigeration, it should not be placed back in the refrigerator. If these conditions are exceeded, the medication must be discarded.

EMGALITY 120 mg/mL is administered subcutaneously. It can be injected into the abdomen, thigh, back of the upper arm, or buttocks. The injection should be performed by a healthcare provider or as instructed by a healthcare professional.

The most serious risks associated with EMGALITY 120 mg/mL include serious hypersensitivity reactions, such as anaphylaxis and angioedema, new-onset or worsening of pre-existing hypertension, and serious complications of constipation. Patients should be monitored for these risks and seek immediate medical attention if they occur.

EMGALITY 120 mg/mL is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or any of the excipients. Patients with a history of severe hypersensitivity reactions to this medication or its components should avoid using it. Always consult with a healthcare provider to determine if EMGALITY 120 mg/mL is appropriate for your specific condition.